Barclays now sees two Fed cuts this year, says jumbo Fed cuts ’very unlikely’
Anish Patel, the Chief Operating Officer of Enliven Therapeutics, Inc. (NASDAQ:ELVN), recently sold shares in the company amounting to $146,205. The transaction involved the sale of 6,667 shares of common stock, executed at an average price of $21.9298 per share. The sales were conducted on February 7, 2025, as part of a pre-established Rule 10b5-1 trading plan. According to InvestingPro data, the company, currently valued at $1.06 billion, maintains strong financial health with a GOOD overall score and holds more cash than debt on its balance sheet.
Following this transaction, Patel retains indirect ownership of 329,977 shares through the Patel / Dong Family Trust. Additionally, Patel acquired stock options for 171,000 shares at a conversion price of $22.47, with these options set to expire on February 6, 2035. The options will begin vesting on February 6, 2026, with a quarter of the shares vesting initially and the remainder vesting monthly thereafter, contingent upon continued service with the company. With analyst targets ranging from $33 to $42 per share, InvestingPro subscribers can access additional insights and 6 key ProTips about ELVN’s valuation and growth prospects.
In other recent news, Enliven Therapeutics has made significant strides in the development of its tyrosine kinase inhibitors (TKIs) for cancer treatment, attracting positive ratings from several analyst firms. BTIG initiated coverage on Enliven Therapeutics with a Buy rating and a price target of $42.00, highlighting the company’s potential to address unmet needs within large and lucrative markets such as chronic myeloid leukemia (CML) and HER2 in solid tumors. Additionally, Clear Street set a Buy rating on Enliven Therapeutics with a $36.00 target, citing the company’s strong foothold in the TKI market and anticipated progress in the next 12 to 18 months.
Similarly, Baird maintained an Outperform rating on Enliven Therapeutics and raised the stock’s price target to $40 from $32 following promising data from ongoing trials and recent third-quarter 2024 results. The firm noted the approval of Scemblix for front-line CML treatment and the potential of Enliven’s ELVN-001 in the second-line and beyond CML market. These recent developments underline the progress Enliven Therapeutics has made in its strategic focus on developing treatments for CML and solid tumors.
As the company moves forward, investors will be keeping a close eye on key clinical data expected to be released over the next 12-18 months, which could lead to substantial stock appreciation and pivotal catalysts for both of Enliven’s programs in 2025. These recent analyst ratings and price targets reflect a high level of confidence in Enliven Therapeutics’ future prospects in the TKI market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.